MX2017000094A - PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS. - Google Patents

PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.

Info

Publication number
MX2017000094A
MX2017000094A MX2017000094A MX2017000094A MX2017000094A MX 2017000094 A MX2017000094 A MX 2017000094A MX 2017000094 A MX2017000094 A MX 2017000094A MX 2017000094 A MX2017000094 A MX 2017000094A MX 2017000094 A MX2017000094 A MX 2017000094A
Authority
MX
Mexico
Prior art keywords
amino acid
acid sequences
mutein
amyloid
products based
Prior art date
Application number
MX2017000094A
Other languages
English (en)
Inventor
Barghorn Stefan
Hillen Heinz
Striebinger Andreas
Giaisi Simone
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of MX2017000094A publication Critical patent/MX2017000094A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La invención se refiere a productos inmunogénicos basados en secuencias de aminoácidos de muteína amiloide ß (Aß), en particular a oligómeros de muteínas Aß, y al uso de estos productos en la diagnosis, tratamiento y prevención de condiciones tal como amiloidosis y para identificar agentes capaces de unirse a estos productos.
MX2017000094A 2014-07-07 2015-07-06 PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS. MX2017000094A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462021308P 2014-07-07 2014-07-07
PCT/EP2015/065362 WO2016005328A2 (en) 2014-07-07 2015-07-06 IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2017000094A true MX2017000094A (es) 2017-04-27

Family

ID=53525183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000094A MX2017000094A (es) 2014-07-07 2015-07-06 PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.

Country Status (11)

Country Link
US (2) US20160000891A1 (es)
EP (1) EP3166969A2 (es)
JP (3) JP2017532289A (es)
CN (1) CN107074924A (es)
AU (2) AU2015286824A1 (es)
CA (1) CA2954031A1 (es)
IL (1) IL249925B (es)
MX (1) MX2017000094A (es)
RU (1) RU2750268C2 (es)
SG (1) SG11201700071WA (es)
WO (1) WO2016005328A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631195C (en) 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
JP2017532289A (ja) * 2014-07-07 2017-11-02 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
CN109477832A (zh) * 2016-09-06 2019-03-15 富士瑞必欧株式会社 甲状腺球蛋白的测定方法及测定试剂
JP6999561B2 (ja) * 2016-09-13 2022-02-10 富士レビオ株式会社 心筋トロポニンの測定方法及び測定試薬
CN110412294B9 (zh) * 2019-08-07 2023-05-26 深圳市新产业生物医学工程股份有限公司 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白校准品稳定性的方法
CN112851786B (zh) * 2019-11-12 2022-11-15 深圳市新产业生物医学工程股份有限公司 可溶性的Aβ1-42变体、Aβ1-42校准品及试剂盒
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
EP4230645A1 (en) * 2022-02-22 2023-08-23 Technische Universität München Peptidic inhibitors of amyloid self- and cross-assembly
CN117700525B (zh) * 2024-02-05 2024-06-18 上海良润生物医药科技有限公司 一种多肽改造体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CN101432302A (zh) * 2005-11-30 2009-05-13 艾博特公司 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
CN102203124A (zh) * 2008-07-25 2011-09-28 雅培制药有限公司 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途
US8987419B2 (en) * 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX358739B (es) * 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
JP2017532289A (ja) * 2014-07-07 2017-11-02 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用

Also Published As

Publication number Publication date
WO2016005328A2 (en) 2016-01-14
JP2021001203A (ja) 2021-01-07
EP3166969A2 (en) 2017-05-17
JP2023036606A (ja) 2023-03-14
JP2017532289A (ja) 2017-11-02
AU2021200575A1 (en) 2021-03-04
IL249925B (en) 2021-09-30
IL249925A0 (en) 2017-03-30
RU2750268C2 (ru) 2021-06-25
BR112017000428A2 (pt) 2017-10-31
US20160000891A1 (en) 2016-01-07
CA2954031A1 (en) 2016-01-14
AU2015286824A1 (en) 2017-02-09
CN107074924A (zh) 2017-08-18
SG11201700071WA (en) 2017-02-27
RU2017103527A3 (es) 2019-02-19
US20240075114A1 (en) 2024-03-07
WO2016005328A3 (en) 2016-05-26
RU2017103527A (ru) 2018-08-07

Similar Documents

Publication Publication Date Title
MX2017000094A (es) PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.
ZA201708692B (en) Antibacterial compounds
EA201990043A1 (ru) Антибактериальные соединения
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
GB2541571A (en) Pharmaceutical compositions
MX2017001971A (es) Composiciones antimetanogenicas y sus usos.
WO2016149501A3 (en) Modified therapeutic agents and compositions thereof
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
HK1258999A1 (zh) 用於治療肝臟和維持肝臟健康的組合物、方法和藥物組合物
MX2016011746A (es) Casete de fluido con seguro de alineacion que tiene una tolerancia a la inclinacion mejorada, asi como un aparato de tratamiento de la sangre.
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy
MX2017013879A (es) Composiciones que comprenden anakinra.
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
WO2017079403A3 (en) Polymeric nanoparticles
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
WO2016073493A3 (en) Antifibrinolytic compounds
WO2016046759A3 (en) Compositions and methods for treating friedreich's ataxia
PH12017501918A1 (en) Multi-peptide composition
WO2017042577A8 (en) Novel therapy
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci